When Bristol Myers Squibb completed its $74 billion megatakeover of Celgene late last year, one of the centerpieces of the deal was multiple myeloma blockbuster Revlimid. And now, with a troubling patent challenge off the books, the drug could just keep on growing.
Revlimid nabbed $11.11 billion in sales in 2019, ranking it among pharma's elite sellers. Because Bristol closed its acquisition of Celgene in November, Evaluate did not forecast what 2026 sales could look like, but a lack of generics challengers and just two other biologics on the market could easily spell a sales bump in the coming years.
Revlimid for years was known for its aggressive price hikes that caught flack from consumers and politicians but has mostly escaped unscathed on its march to blockbuster sales.
Celgene escaped a spooky patent challenge last year from Alvogen that put a temporary damper on Bristol investors' hopes in the merger. But with that challenge off the table, Revlimid is in the clear to keep pursuing growth under its new parent company.